.jpeg)
2026-08-25 08:10:21
Belzutifan (WELIREG) is a first-in-class oral HIF-2α inhibitor approved for VHL-associated renal cell carcinoma, CNS hemangioblastomas, and pancreatic neuroendocrine tumors. This guide outlines dosing, time to response, follow-up schedules, discontinuation criteria, and long-term management strategies for patients and clinicians.
2026-08-24 07:51:59
Lapatinib is an oral dual HER2/EGFR tyrosine kinase inhibitor. Key adverse effects to monitor during treatment include diarrhea, skin reactions, and hepatic function changes. This article outlines recognition points and graded management strategies.
2026-08-21 03:30:56
Cemiplimab is a PD-1 immune checkpoint inhibitor that restores T-cell antitumor immunity. It is FDA-approved for advanced basal cell carcinoma, cutaneous squamous cell carcinoma, and selected cases of non-small cell lung cancer.
2026-08-20 03:48:01
Capmatinib (brand name Tabrecta) is a highly selective MET tyrosine kinase inhibitor developed by Novartis, approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article systematically examines its positioning as a second-generation MET inhibitor with superior selectivity and intracranial activity, provides detailed adverse effect incidence data from the pivotal GEOMETRY mono-1 trial, and presents grade-based management strategies for peripheral edema, hepatotoxicity, gastrointestinal effects, and other toxicities, along with dose-modification protocols and special-population guidance to support safe and effective targeted therapy.
2026-08-20 03:12:46
Dabrafenib (brand name TAFINLAR) is a highly selective oral BRAF kinase inhibitor, most commonly used in combination with the MEK inhibitor trametinib for the treatment of BRAF V600–mutant solid tumors including melanoma, non-small cell lung cancer, anaplastic thyroid cancer, and pediatric low-grade glioma. This article provides a structured overview of its approved indications, the characteristic pyrexia syndrome and other adverse effects, grade-based management strategies, dose-reduction and discontinuation protocols, and special-population safety considerations to support comprehensive treatment management.
2026-08-20 03:03:58
Adagrasib (brand name Krazati) is the second approved highly selective, covalent KRAS G12C inhibitor for patients with KRAS G12C–mutant non-small cell lung cancer and colorectal cancer. This article systematically reviews the drug's adverse-effect profile—centered on gastrointestinal toxicity and hepatotoxicity—and provides structured, grade-based management strategies for diarrhea, liver enzyme elevation, fatigue, QTc prolongation, and hematologic effects, along with dose-modification principles to help patients and clinical teams maintain the optimal balance between efficacy and safety throughout treatment.
2026-08-20 02:55:43
Tepotinib (brand name TEPMETKO) is a highly selective oral MET tyrosine kinase inhibitor approved for adults with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations. This article provides a structured guide to the standard dosing regimen, proactive management of peripheral edema and other adverse effects, dose-reduction and discontinuation criteria, risk assessment in special populations, drug-interaction considerations, and a recommended monitoring schedule to support safe and effective targeted therapy.
2026-08-19 06:59:25
Tivozanib is an oral VEGFR tyrosine kinase inhibitor used in advanced renal cell carcinoma, administered at 1.34 mg once daily in a 21-days-on, 7-days-off, 28-day cycle. This article covers standard dosing, dose modification for adverse events, and reduced dosing for moderate hepatic impairment.
2026-08-19 04:40:21
Vemurafenib is an oral small-molecule BRAF kinase inhibitor designed to selectively target BRAF V600E and related mutations. This article explores its molecular mechanism, the essential role of BRAF genetic testing, and its positioning within precision oncology.
2026-08-17 06:12:53
Sotorasib (brand name: Lumakras), developed by Amgen, is the world's first KRAS G12C inhibitor approved by the U.S. FDA in May 2021. It is indicated for adults with KRAS G12C-mutant advanced non-small cell lung cancer and metastatic colorectal cancer.
2026-08-14 03:20:41
This article systematically interprets Osimertinib, a core therapeutic drug for EGFR mutation-positive non-small cell lung cancer, covering pharmacological efficacy, common and serious adverse reactions, indications, usage and dosage, drug interactions and key points for special populations, providing a comprehensive reference for standardized clinical medication.
2026-08-14 02:50:16
Sotorasib (brand name Lumakras) is the world's first approved targeted drug for KRAS G12C mutations, used in precision treatment of non-small cell lung cancer and colorectal cancer. This article explains its efficacy limits, approved indications, mechanism of action, and safety considerations to help patients set realistic treatment expectations.
